/PLXP
PLXP Stock - PLx Pharma Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$0.09+0.00%
+$0.00 (+0.00%) • Apr 12
35
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PLXP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.09 – $0.09
TARGET (TP)$0.10
STOP LOSS$0.08
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.92
52W High$3.41
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $8.21M | $30,430 | $565,464 | $753,108 | $778,657 |
| Gross Profit | $3.40M | $30,430 | $565,464 | $753,108 | $778,657 |
| Gross Margin | 41.5% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-40,790,000 | $-13,459,112 | $-14,202,293 | $-10,961,157 | $-15,847,842 |
| Net Income | $-51,460,000 | $-15,102,990 | $-21,339,121 | $896,480 | $-15,346,731 |
| Net Margin | -626.9% | -49631.9% | -3773.7% | 119.0% | -1970.9% |
| EPS | $-2.18 | $-1.55 | $-2.39 | $0.10 | $-2.19 |
Company Overview
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PLXPBeat Rate
53%
Last 17 quarters
Avg Surprise
-14.4%
EPS vs Estimate
Beats / Misses
9/8
Last 12 quarters
Latest EPS
$-0.73
Q1 2023
EPS Surprise History
Q2 21
-47.1%
$-0.25vs$-0.17
Q3 21
-60.9%
$-0.37vs$-0.23
Q4 21
+21.3%
$-0.37vs$-0.47
Q1 22
-5.8%
$-0.73vs$-0.69
Q2 22
+4.3%
$-0.66vs$-0.69
Q3 22
+7.1%
$-0.52vs$-0.56
Q4 22
+15.9%
$-0.37vs$-0.44
Q1 23
-160.7%
$-0.73vs$-0.28
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 9, 2023 | — | — | — | — |
Q3 2023 | Aug 10, 2023 | $-0.28 | — | — | — |
Q2 2023 | Apr 3, 2023 | $-0.28 | — | — | — |
Q1 2023 | Mar 10, 2023 | $-0.28 | $-0.73 | -160.7% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.44 | $-0.37 | +15.9% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-0.56 | $-0.52 | +7.1% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-0.69 | $-0.66 | +4.3% | ✓ BEAT |
Q1 2022 | Mar 11, 2022 | $-0.69 | $-0.73 | -5.8% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.47 | $-0.37 | +21.3% | ✓ BEAT |
Q3 2021 | Aug 6, 2021 | $-0.23 | $-0.37 | -60.9% | ✗ MISS |
Q2 2021 | May 14, 2021 | $-0.17 | $-0.25 | -47.1% | ✗ MISS |
Q1 2021 | Mar 12, 2021 | $-0.29 | $-0.38 | -31.0% | ✗ MISS |
Q4 2020 | Nov 13, 2020 | $-0.41 | $-0.40 | +2.4% | ✓ BEAT |
Q3 2020 | Aug 14, 2020 | $-0.42 | $-0.45 | -7.1% | ✗ MISS |
Q2 2020 | May 15, 2020 | $-0.40 | $-0.37 | +7.5% | ✓ BEAT |
Q1 2020 | Mar 13, 2020 | $-0.48 | $-0.45 | +6.2% | ✓ BEAT |
Q4 2019 | Nov 8, 2019 | $-0.50 | $-0.46 | +8.0% | ✓ BEAT |
Q3 2019 | Aug 9, 2019 | $-0.44 | $-0.49 | -11.4% | ✗ MISS |
Q2 2019 | May 10, 2019 | $-0.33 | $-0.36 | -9.1% | ✗ MISS |
Q1 2019 | Mar 8, 2019 | $-0.37 | $-0.31 | +16.2% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about PLXP
What is PLXP's current stock price?
PLx Pharma Inc. (PLXP) is currently trading at $0.09 per share. The stock has moved +0.00% today.
What is the analyst price target for PLXP?
No analyst price targets are currently available for this stock.
What sector is PLx Pharma Inc. in?
PLx Pharma Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is PLXP's market cap?
PLx Pharma Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PLXP pay dividends?
No, PLx Pharma Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPDN
Applied DNA Sciences, Inc.
$5.62
Mkt Cap: $0.0B
ATNX
Athenex, Inc.
$0.20
Mkt Cap: $0.0B
AWH
Aspira Women's Health Inc.
$0.08
Mkt Cap: $0.0B
BPTS
Biophytis S.A.
$8.22
Mkt Cap: $0.0B
EIGRQ
Eiger BioPharmaceuticals, Inc.
$8.50
Mkt Cap: $0.0B
HIND
Vyome Holdings, Inc.
$3.68
Mkt Cap: $0.0B
NOVN
Novan, Inc.
$0.09
Mkt Cap: $0.0B
NTBL
Notable Labs, Ltd.
$0.25
Mkt Cap: $0.0B
PTN
Palatin Technologies, Inc.
$17.05
Mkt Cap: $0.4B
SQL
SeqLL Inc.
$6.60
Mkt Cap: $0.0B
Explore stocks similar to PLXP for comparison